Related Experiment Video
Updated: Dec 27, 2025
08:05
Detection and Isolation of Cancer in Prostate Biopsies Using Stimulated Raman Histology and Artificial Intelligence
Published on: June 10, 2025
1.0K
Can the Irisin be a Biomarker for Prostate Cancer? A Case Control Study
Rahmi Aslan1, Hamit Hakan Alp2, Recep Eryılmaz1
1Department of Urology, Faculty of Medicine, Van Yuzuncu Yıl University, 65080-Van, Turkey.
Asian Pacific Journal of Cancer Prevention : APJCP
|February 28, 2020
Summary
Lower irisin levels are associated with prostate cancer (PCa). This study suggests irisin may serve as a diagnostic biomarker for PCa, alongside PSA tests.
Area of Science:
- Endocrinology
- Oncology
- Biochemistry
Background:
- Irisin, an adipokine, has demonstrated associations with various cancers.
- Understanding irisin's role in prostate cancer (PCa) is crucial for diagnostic advancements.
Purpose of the Study:
- To investigate the relationship between irisin levels and PCa.
- To evaluate irisin's potential as a diagnostic biomarker for PCa.
Main Methods:
- Serum samples from 50 PCa patients and 30 healthy males were analyzed.
- Free PSA, total PSA, and irisin levels were measured.
- Irisin levels were correlated with Gleason scores and T stage; ROC analysis was performed.
Main Results:
- PCa patients exhibited significantly lower irisin levels compared to healthy controls (p<0.05).
- Free and total PSA levels were significantly higher in the PCa group (p<0.05).
- Irisin demonstrated 80.5% sensitivity and 90% specificity for PCa detection with a cut-off of 8.1.
Conclusions:
- Reduced serum irisin levels are characteristic of PCa.
- Irisin shows promise as a complementary biomarker for PCa diagnosis.
- Further research can validate irisin's utility in clinical settings.
